These findings may serve to explain the contrasting clinical data that establish EGFR as a predictor of poor prognosis for BC patients [6], yet administration of monotherapies directed against EGFR or in conjunction with other chemotherapies has failed to provide a clinical benefit for BC patients [7-9]. The gene discussed is EGFR; the disease is breast cancer.